Pills from pipes: Flow microreactors chart the route to container-scale, on-demand drug manufacturing
A new review distills a decade of evidence — 780+ industrial installations, linezolid made continuously in 27 minutes, project value up 30% — into a blueprint for distributed pharmaceutical production
image:
Integrated flow purification combines separation and isolation with continuous synthesis.
Artificial intelligence and real-time monitoring support data-driven process optimization.
Integrated purification helps reduce waste, solvent use, and intermediate processing steps.
Industrial flow platforms combine reaction, purification, and product isolation in one process.
Modular plants offer flexible production, from active ingredients to distributed manufacturing.
view more
Credit: Oshchepkov M., Kochetkov K., Pavlov P., et al., (2026). Continuous microreactor technology to container-scale manufacturing: A blueprint for the next generation pharma industry. The Innovation Insights 1(1), 100016.
A review published in The Innovation Insights argues that the pharmaceutical industry's next decade belongs to pipes, not vats: continuous-flow microreactor technology, it concludes, is the blueprint for sustainable, flexible, and decentralized drug manufacturing. Conventional plants make medicines batch by batch, pausing to isolate and purify intermediates at every step—slow, solvent-hungry, and hard to retool. Flow chemistry instead pumps reagents through millimeter-scale channels under tight control. Roughly one hundred active pharmaceutical ingredients have now been synthesized, at least in part, under continuous-flow conditions. The industrial base is already substantial. More than 780 industrial microreactor installations operate worldwide, and over 250 chemical companies have adopted microflow technology; market analyses value the microreactor market at about 597.9 million US dollars in 2024, projected toward 1.4 billion by 2033. The review's case studies include a fully continuous seven-step synthesis of the antibiotic linezolid finished in 27 minutes with a 73 percent isolated yield, against more than 60 hours for conventional routes; a ten-step route to oseltamivir with an overall yield of 58 percent and reagent residence times of 3.5 minutes; Eli Lilly's cGMP production of the cancer drug candidate prexasertib, 24 kilograms at roughly 3 kilograms per day; and Sanofi's semi-continuous artemisinin line producing about 50 to 60 tonnes per year. What the review adds is the synthesis of these threads into a single architecture. Scale-up by parallel numbering-up sidesteps the limits of simply building bigger reactors. Inline process analytical technology and machine-learning models enable self-optimizing reactors and predictive quality control. Integrated purification—liquid-liquid extraction, membrane separation, scavenger cartridges, continuous chromatography, and microfluidic crystallization—closes the gap between reaction and product. The endpoint is the modular, container-based "mini-plant": review-cited analyses indicate modular continuous plants can come online two to three times faster than conventional facilities and raise project net present value by more than 30 percent. Regulatory acceptance is following: FDA guidance Q13 sets out expectations for continuous manufacturing of drug substances and products. The authors are careful about limits. Continuous flow is not a universal replacement for batch manufacturing: suspended solids can clog channels, very slow reactions lose their advantage, continuous chromatography often sacrifices isolated yield, and membrane separations remain hard to fabricate robustly. Machine-learning approaches are constrained by small, biased datasets and the black-box problem of model interpretability. Shifting an industry built on batch production is also capital-intensive and cultural, requiring retrained specialists and adapted regulatory frameworks. Even with those caveats, the review's conclusion is direct: the convergence of flow chemistry, digitalization, automation, and AI-driven control constitutes a new paradigm for pharmaceutical production—one that could one day make essential medicines where and when they are needed.